Articles related to RESEARCH & CLINICAL TRIALS

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix

The reseachers acknowledge that the Delphi approach favors compounds already studied and may exclude agents identifiable only through high-throughput screening.

“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics

“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer

“If the systems of the site are compromised and being held for ransom, there would be no way to continue that trial, and [it would likely be] impossible to participate in other trials.” — Jeff Patton, MD, OneOncology